Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 12/20 | 0.72 |
| ▸ | PGR | P06401 | 2/20 | 0.72 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3289356 | 0.90 | AR (0.57) | ARPGRCYP2C19 | |
| SCHEMBL1377143 | 0.90 | AR (0.57) | ARPGRCYP2C19 | |
| SCHEMBL3295001 | 0.90 | AR (0.58) | ARPGRS1PR1CYP2C19ABCB11 | |
| SCHEMBL3295006 | 0.90 | AR (0.58) | ARPGRS1PR1CYP2C19ABCB11 | |
| SCHEMBL3288341 | 0.89 | AR (0.74) | ARPGRS1PR1RXRARXRB | |
| SCHEMBL3288343 | 0.89 | AR (0.74) | ARPGRS1PR1RXRARXRB | |
| SCHEMBL1376531 | 0.88 | AR (0.61) | ARPGRRXRARXRBRXRG | |
| SCHEMBL1379543 | 0.87 | PGR (0.54) | ARPGRCYP2C19 | |
| SCHEMBL3291874 | 0.87 | PGR (0.54) | ARPGRCYP2C19 | |
| SCHEMBL4903805 | 0.87 | PGR (0.55) | ARPGRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194536-A1 | Cyanoarylamines | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194536-A1 | Cyanoarylamines | EDNRA, CYP19A1, HSD17B11 | AR 84/4885PGR 64/4885S1PR1 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.